Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Go back to Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease| Along Mobile Technologies, Inc. (NASDAQ: AGMB) | Delayed: 9.26 +0.15 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.11 | 52 Week High | $0.01 | |||
| Open | $9.15 | 52 Week Low | $0.01 | |||
| Day High | $9.44 | P/E | N/A | |||
| Day Low | $8.90 | EPS | $0.00 | |||
| Volume | 84,322 | |||||



